Recombinant activated factor VII for refractory bleeding after acute aortic dissection surgery: A propensity score analysis

Luigi Tritapepe, Vincenzo De Santis, Domenico Vitale, Cecilia Nencini, Fabio Pellegrini, Giovanni Landoni, Federico Toscano, Fabio Miraldi, Paolo Pietropaoli

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: The aim of this study was to assess safety and effectiveness of recombinant activated factor VII (rFVIIa) in patients with refractory bleeding undergoing acute aortic dissection surgery with deep hypothermic circulatory arrest. DESIGN: Propensity score-matched analysis. SETTING: University hospital. PATIENTS: Twenty-three cardiac surgery patients receiving rFVIIa compared with 23 matched controls. INTERVENTIONS: An intravenous bolus of rFVIIa (70 μg/kg) was administered at the end of a complete transfusion protocol. Five patients received rFVIIa in the operating room, and 18 patients received rFVIIa in the intensive care unit. Four of the intensive care unit patients required a second dose. MEASUREMENTS AND MAIN RESULTS: Blood loss and transfusion requirements were significantly reduced in the period after rFVIIa administration. A highly significant reduction in hourly blood loss was found at -1 hr vs. 0 hrs and 0 hrs vs. 1 hr (-194 and -77.5 mL, respectively; both adjusted p <.001). In addition, significant improvements of international normalized ratio (p <.001), partial thromboplastin time (p <.001), platelet count (p <.001), fibrinogen (p <.001), and antithrombin (p <.001) were detected after rFVIIa administration. The two groups did not differ regarding adverse events. CONCLUSIONS: rFVIIa was successfully used as an additional therapy both during and after acute aortic dissection surgery with deep hypothermic circulatory arrest, when bleeding was refractory to conventional methods. Randomized studies are necessary to confirm the safety and efficacy of rFVIIa in this setting.

Original languageEnglish
Pages (from-to)1685-1690
Number of pages6
JournalCritical Care Medicine
Volume35
Issue number7
DOIs
Publication statusPublished - Jul 2007

Fingerprint

Factor VIIa
Propensity Score
Dissection
Hemorrhage
Deep Hypothermia Induced Circulatory Arrest
Intensive Care Units
Safety
recombinant FVIIa
International Normalized Ratio
Antithrombins
Partial Thromboplastin Time
Operating Rooms
Platelet Count
Blood Transfusion
Fibrinogen
Thoracic Surgery

Keywords

  • Bleeding
  • Cardiac surgery
  • Hemostasis
  • Recombinant activated factor VII
  • Thromboembolism
  • Transfusion

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Recombinant activated factor VII for refractory bleeding after acute aortic dissection surgery : A propensity score analysis. / Tritapepe, Luigi; De Santis, Vincenzo; Vitale, Domenico; Nencini, Cecilia; Pellegrini, Fabio; Landoni, Giovanni; Toscano, Federico; Miraldi, Fabio; Pietropaoli, Paolo.

In: Critical Care Medicine, Vol. 35, No. 7, 07.2007, p. 1685-1690.

Research output: Contribution to journalArticle

Tritapepe, L, De Santis, V, Vitale, D, Nencini, C, Pellegrini, F, Landoni, G, Toscano, F, Miraldi, F & Pietropaoli, P 2007, 'Recombinant activated factor VII for refractory bleeding after acute aortic dissection surgery: A propensity score analysis', Critical Care Medicine, vol. 35, no. 7, pp. 1685-1690. https://doi.org/10.1097/01.CCM.0000269033.89428.B3
Tritapepe, Luigi ; De Santis, Vincenzo ; Vitale, Domenico ; Nencini, Cecilia ; Pellegrini, Fabio ; Landoni, Giovanni ; Toscano, Federico ; Miraldi, Fabio ; Pietropaoli, Paolo. / Recombinant activated factor VII for refractory bleeding after acute aortic dissection surgery : A propensity score analysis. In: Critical Care Medicine. 2007 ; Vol. 35, No. 7. pp. 1685-1690.
@article{cdf4034ff3224bc49050aa494b4dee77,
title = "Recombinant activated factor VII for refractory bleeding after acute aortic dissection surgery: A propensity score analysis",
abstract = "OBJECTIVE: The aim of this study was to assess safety and effectiveness of recombinant activated factor VII (rFVIIa) in patients with refractory bleeding undergoing acute aortic dissection surgery with deep hypothermic circulatory arrest. DESIGN: Propensity score-matched analysis. SETTING: University hospital. PATIENTS: Twenty-three cardiac surgery patients receiving rFVIIa compared with 23 matched controls. INTERVENTIONS: An intravenous bolus of rFVIIa (70 μg/kg) was administered at the end of a complete transfusion protocol. Five patients received rFVIIa in the operating room, and 18 patients received rFVIIa in the intensive care unit. Four of the intensive care unit patients required a second dose. MEASUREMENTS AND MAIN RESULTS: Blood loss and transfusion requirements were significantly reduced in the period after rFVIIa administration. A highly significant reduction in hourly blood loss was found at -1 hr vs. 0 hrs and 0 hrs vs. 1 hr (-194 and -77.5 mL, respectively; both adjusted p <.001). In addition, significant improvements of international normalized ratio (p <.001), partial thromboplastin time (p <.001), platelet count (p <.001), fibrinogen (p <.001), and antithrombin (p <.001) were detected after rFVIIa administration. The two groups did not differ regarding adverse events. CONCLUSIONS: rFVIIa was successfully used as an additional therapy both during and after acute aortic dissection surgery with deep hypothermic circulatory arrest, when bleeding was refractory to conventional methods. Randomized studies are necessary to confirm the safety and efficacy of rFVIIa in this setting.",
keywords = "Bleeding, Cardiac surgery, Hemostasis, Recombinant activated factor VII, Thromboembolism, Transfusion",
author = "Luigi Tritapepe and {De Santis}, Vincenzo and Domenico Vitale and Cecilia Nencini and Fabio Pellegrini and Giovanni Landoni and Federico Toscano and Fabio Miraldi and Paolo Pietropaoli",
year = "2007",
month = "7",
doi = "10.1097/01.CCM.0000269033.89428.B3",
language = "English",
volume = "35",
pages = "1685--1690",
journal = "Critical Care Medicine",
issn = "0090-3493",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Recombinant activated factor VII for refractory bleeding after acute aortic dissection surgery

T2 - A propensity score analysis

AU - Tritapepe, Luigi

AU - De Santis, Vincenzo

AU - Vitale, Domenico

AU - Nencini, Cecilia

AU - Pellegrini, Fabio

AU - Landoni, Giovanni

AU - Toscano, Federico

AU - Miraldi, Fabio

AU - Pietropaoli, Paolo

PY - 2007/7

Y1 - 2007/7

N2 - OBJECTIVE: The aim of this study was to assess safety and effectiveness of recombinant activated factor VII (rFVIIa) in patients with refractory bleeding undergoing acute aortic dissection surgery with deep hypothermic circulatory arrest. DESIGN: Propensity score-matched analysis. SETTING: University hospital. PATIENTS: Twenty-three cardiac surgery patients receiving rFVIIa compared with 23 matched controls. INTERVENTIONS: An intravenous bolus of rFVIIa (70 μg/kg) was administered at the end of a complete transfusion protocol. Five patients received rFVIIa in the operating room, and 18 patients received rFVIIa in the intensive care unit. Four of the intensive care unit patients required a second dose. MEASUREMENTS AND MAIN RESULTS: Blood loss and transfusion requirements were significantly reduced in the period after rFVIIa administration. A highly significant reduction in hourly blood loss was found at -1 hr vs. 0 hrs and 0 hrs vs. 1 hr (-194 and -77.5 mL, respectively; both adjusted p <.001). In addition, significant improvements of international normalized ratio (p <.001), partial thromboplastin time (p <.001), platelet count (p <.001), fibrinogen (p <.001), and antithrombin (p <.001) were detected after rFVIIa administration. The two groups did not differ regarding adverse events. CONCLUSIONS: rFVIIa was successfully used as an additional therapy both during and after acute aortic dissection surgery with deep hypothermic circulatory arrest, when bleeding was refractory to conventional methods. Randomized studies are necessary to confirm the safety and efficacy of rFVIIa in this setting.

AB - OBJECTIVE: The aim of this study was to assess safety and effectiveness of recombinant activated factor VII (rFVIIa) in patients with refractory bleeding undergoing acute aortic dissection surgery with deep hypothermic circulatory arrest. DESIGN: Propensity score-matched analysis. SETTING: University hospital. PATIENTS: Twenty-three cardiac surgery patients receiving rFVIIa compared with 23 matched controls. INTERVENTIONS: An intravenous bolus of rFVIIa (70 μg/kg) was administered at the end of a complete transfusion protocol. Five patients received rFVIIa in the operating room, and 18 patients received rFVIIa in the intensive care unit. Four of the intensive care unit patients required a second dose. MEASUREMENTS AND MAIN RESULTS: Blood loss and transfusion requirements were significantly reduced in the period after rFVIIa administration. A highly significant reduction in hourly blood loss was found at -1 hr vs. 0 hrs and 0 hrs vs. 1 hr (-194 and -77.5 mL, respectively; both adjusted p <.001). In addition, significant improvements of international normalized ratio (p <.001), partial thromboplastin time (p <.001), platelet count (p <.001), fibrinogen (p <.001), and antithrombin (p <.001) were detected after rFVIIa administration. The two groups did not differ regarding adverse events. CONCLUSIONS: rFVIIa was successfully used as an additional therapy both during and after acute aortic dissection surgery with deep hypothermic circulatory arrest, when bleeding was refractory to conventional methods. Randomized studies are necessary to confirm the safety and efficacy of rFVIIa in this setting.

KW - Bleeding

KW - Cardiac surgery

KW - Hemostasis

KW - Recombinant activated factor VII

KW - Thromboembolism

KW - Transfusion

UR - http://www.scopus.com/inward/record.url?scp=34250901460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250901460&partnerID=8YFLogxK

U2 - 10.1097/01.CCM.0000269033.89428.B3

DO - 10.1097/01.CCM.0000269033.89428.B3

M3 - Article

C2 - 17522585

AN - SCOPUS:34250901460

VL - 35

SP - 1685

EP - 1690

JO - Critical Care Medicine

JF - Critical Care Medicine

SN - 0090-3493

IS - 7

ER -